Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP707 in chronic painful diabetic polyneuropathy
2022-500897-32-00Phase 3Completed
- Sponsor
- Cannaxan
- Start
- Jun 2023
- Modality
- Small Molecules, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing AP707 (verum) with Placebo (2 arms). Started Jun 2023; status: completed.
02
Drugs
adezunap
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on 2022-500897-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500897-32-00.